Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma
2015-003128-30Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and Hodgkin lymphoma (HL), sponsored by University of Cologne. Primary endpoint: Disease stabilization/response rate after six 21-day cycles of ibrutinib. Started Dec 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2015-003128-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003128-30.